Tags

Type your tag names separated by a space and hit enter

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
Arch Virol. 2006 May; 151(5):921-31.AV

Abstract

Two-fold immunization of Balb/c mice with a vaccinia virus recombinant expressing the NP protein of influenza A/PR8/34 (H1N1) virus under the control of a strong synthetic promoter induced specific antibodies and protected animals against low-dose challenge by mouse-adapted heterosubtypic variants of human A/Aichi2/68 (H3N2) and avian A/Mallard/Pennsylvania/10218/84 (H5N2) influenza virus strains. The surviving immunized animals had lower anti-hemagglutinin antibody titers compared to non-immunized mice. There was no difference in viral titers in lungs of immunized and non-immunized animals that succumbed to the infection. In order to try to increase immune system presentation of NP-protein-derived peptides, and thereby increase their immunogenicity, we constructed another vaccinia-based NP-expressing recombinant containing a rapid proteolysis signal covalently bound to the NP protein. This sequence, derived from the mouse ornithine decarboxylase gene has been shown to increase degradation of various proteins. However, we found that when used as part of a recombinant NP, this signal neither increased its proteolytic degradation, nor was it more efficient in the induction of a protective response against influenza infection.

Authors+Show Affiliations

Institute of Gene Biology RAS, Moscow, Russia. altstein.ad@relcom.ruNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16292596

Citation

Altstein, A D., et al. "Immunization With Influenza a NP-expressing Vaccinia Virus Recombinant Protects Mice Against Experimental Infection With Human and Avian Influenza Viruses." Archives of Virology, vol. 151, no. 5, 2006, pp. 921-31.
Altstein AD, Gitelman AK, Smirnov YA, et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol. 2006;151(5):921-31.
Altstein, A. D., Gitelman, A. K., Smirnov, Y. A., Piskareva, L. M., Zakharova, L. G., Pashvykina, G. V., Shmarov, M. M., Zhirnov, O. P., Varich, N. P., Ilyinskii, P. O., & Shneider, A. M. (2006). Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Archives of Virology, 151(5), 921-31.
Altstein AD, et al. Immunization With Influenza a NP-expressing Vaccinia Virus Recombinant Protects Mice Against Experimental Infection With Human and Avian Influenza Viruses. Arch Virol. 2006;151(5):921-31. PubMed PMID: 16292596.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. AU - Altstein,A D, AU - Gitelman,A K, AU - Smirnov,Y A, AU - Piskareva,L M, AU - Zakharova,L G, AU - Pashvykina,G V, AU - Shmarov,M M, AU - Zhirnov,O P, AU - Varich,N P, AU - Ilyinskii,P O, AU - Shneider,A M, Y1 - 2005/11/15/ PY - 2005/09/05/received PY - 2005/10/13/accepted PY - 2005/11/18/pubmed PY - 2006/7/1/medline PY - 2005/11/18/entrez SP - 921 EP - 31 JF - Archives of virology JO - Arch Virol VL - 151 IS - 5 N2 - Two-fold immunization of Balb/c mice with a vaccinia virus recombinant expressing the NP protein of influenza A/PR8/34 (H1N1) virus under the control of a strong synthetic promoter induced specific antibodies and protected animals against low-dose challenge by mouse-adapted heterosubtypic variants of human A/Aichi2/68 (H3N2) and avian A/Mallard/Pennsylvania/10218/84 (H5N2) influenza virus strains. The surviving immunized animals had lower anti-hemagglutinin antibody titers compared to non-immunized mice. There was no difference in viral titers in lungs of immunized and non-immunized animals that succumbed to the infection. In order to try to increase immune system presentation of NP-protein-derived peptides, and thereby increase their immunogenicity, we constructed another vaccinia-based NP-expressing recombinant containing a rapid proteolysis signal covalently bound to the NP protein. This sequence, derived from the mouse ornithine decarboxylase gene has been shown to increase degradation of various proteins. However, we found that when used as part of a recombinant NP, this signal neither increased its proteolytic degradation, nor was it more efficient in the induction of a protective response against influenza infection. SN - 0304-8608 UR - https://www.unboundmedicine.com/medline/citation/16292596/Immunization_with_influenza_A_NP_expressing_vaccinia_virus_recombinant_protects_mice_against_experimental_infection_with_human_and_avian_influenza_viruses_ L2 - https://dx.doi.org/10.1007/s00705-005-0676-9 DB - PRIME DP - Unbound Medicine ER -